First Italian Conference on Pediatric DIPG/DMG 2023

PROGRAMME

PROGRAMME

08.00-9.00
Participant Registration
09.00
OPENING CEREMONY

Prof. Antonio Scilimati – Professor of Medicinal Chemistry of the Department of Pharmacy-Pharmaceutical Sciences of the University of Bari Aldo Moro

Prof. Grazia Paola Nicchia – ProRector of the University of Bari Aldo Moro
Prof. Francesco Leonetti – Head of the Department of Pharmacy-Pharmaceutical Sciences of the University of Bari Aldo Moro
Prof. Maria Laura Bolognesi – President of the Italian Medicinal Chemistry Division
Dr. Teresa Perillo – Pediatric Honco-hematology, Ospedale Policlinico di Bari (Italy)

Italian DIPG Foundations
– Prof. Giovanni Neri as Representative of Fondazione Onlus MiaNeri (Lazio, Italy), Fondazione GAIA (Marche,Italy), Fondazione Matibellula OdV (Piemonte, Italy) and La Bottega del sorriso (Puglia, Italy), Associazione Il Coraggio dei Bambini (Campania, Italy), HEAL Fondazione (Lazio, Italy)

10.00
From German HIT-HGG trials to the new European trial SIOPE HGG-01: A long and stony way to improve the situation of pediatric DIPG/DMG patients

And

Epigenetic targets and treatment approaches: What can we learn from H3.3K27M isogenic DIPG/DMG models?

Chief of Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University Medical Center Goettingen (Goettingen, Germany)

11.00
Coffee Break​
11.30
Story of adjuvant treatment with nimotuzumab/vinorelbine in DIPG

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano (Italy)

12.00
Histological and molecular approach to diagnosis of diffuse midline glioma H3K27- altered

Dipartimento di Scienze Radiologiche, Oncologiche e Anatomo-Patologiche, Università la Sapienza (Rome, Italy)

12.30
Diffuse midline glioma H3K27-altered and diagnostic challenges: a few interesting cases from pathologist’s perspective

Unit of Human Anatomy and Histology, Department of Translational Biomedicine and Neuroscience (DiBraiN), University of Bari (Italy)

13.00
Lunch
15.00
Neuroradiology in Diffuse Intrinsic Pontine Gliomas/ Diffuse Midline Gliomas

Diagnostic and interventional Neuroradiology, Faculty of Medicine, Department of Neuroradiology, University Hospital of Augsburg (Augsburg, Germany)

15.30
Re-Irradiation of Pediatric Malignant Glioma

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano (Italy)

16.00
The SIOPe DIPG/DMG registry

Pediatria Oncologica, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano (Italy)

16.30
Coffee Break​
17.00
Antiproliferative effects of the unselective tyrosine kinase (TK) and ion channel inhibitor staurosporine on DIPG36 cells: possible role of TK and ion channels as drug targets in DIPG

Department of Pharmacy-Pharmaceutical Sciences, University of Bari (Italy)

17.15
Anatomopathological sign in mice treated with DIPG cells under development

Department of Veterinary Medicine, section of Veterinary Pathology and Comparative Oncology-University of Bari (Italy)

17.30
Oncolytic viruses for pediatric brain tumors: an alternative therapeutic approach

Medical Oncology Department, Universidad de Navarra (Spain)

18.00
Exploiting mass cytometry for the immunophenotyping and the study of the TME in DIPG and other paediatric-type diffuse high-grade gliomas

Paediatric High Grade Glioma Group, Ospedale Pediatrico Bambino Gesù (Rome, Italy)

18.30
Round Table and Closing Remark
20.00
Social Dinner
9.00
A multipronged approach for targeting tumor metabolism in pediatric high grade gliomas

Head of DMG Research Center, University of Zurich (Zurich, Swiss)

9.30
Current insights on DIPG/DMG: the neurosurgeon’s perspective

Department of Translational Biomedicine and Neuroscience (DiBraiN), University of Bari (Italy)

10.00
The Biopsy Dilemma: Balancing Benefits and Risks in DIPG Care

Ospedale Pediatrico Bambino Gesù (Rome, Italy)

10.30
The Liquid biopsy in patients with DMG

HEAD OF LABORATORY OF MOLECULAR ONCOLOGY, D. ROGACHEV CENTER (Moscow, Russia)

11.00
Coffee Break

11.30
Integration of oncological and palliative treatment in pediatric DIPG/DMG: are simultaneous care really feasible?

Pediatric Oncologic Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano (Italy)

12.00
New therapeutic approaches for children with DMG: a PNOC perspective

Neurology UCSF Weill Institute for Neurosciences, School of Medicine, University of California (San Francisco, California)

12.30
Proton Therapy: today and tomorrow

Scientific Director at European Institute of Oncology (Milan), Head of Scientific Board of Linearbeam (Ruvo di Puglia, Italy)

13.00
Lunch
15.00
Towards combinational-therapy for DMG

Departments of Pediatric Oncology / Hematology, Neuro-oncology Research Group, Cancer Center Amsterdam, VU University Medical Center (Amsterdam, The Netherlands)

15.30
Development of novel anticancer compounds targeting mitochondrial ClpP and protein homeostasis

Ontario Institute for Cancer Research/University of Toronto (Toronto, Canada)

16.00
Coffee Break

16.30
Fingerprints for Ligands and Proteins interaction investigation tackling hClpP

Department of Chemical Science, University of Catania (Italy)

17.00
DIPG transcripts meta-analysis

Department of Pharmacy-Pharmaceutical Sciences, University of Bari (Italy)

17.30
Repurposing drugs targeting hClpP by Excalate platform

Discovery Platform Senior Specialist – Dompé farmaceutici

18.00
High Performance Computing and Life Science

HPC Specialist, CINECA, Bologna (Italy)

18.30
Closing Remark